CAMBRIDGE, Mass. — MadeAi, a GenAI-powered evidence synthesis and report generation platform for the life sciences industry, unveiled new capabilities at ISPOR Europe 2025 designed to simplify and accelerate Global Value Dossier (GVD) and Joint Clinical Assessment (JCA) submissions.
The latest release enhances MadeAi’s end-to-end AI-native solution for evidence synthesis, integrating literature review, protocol development, and regulatory-ready reporting. The platform now enables a seamless transition across multiple deliverables, including dossiers, JCA submissions, Clinical Evaluation Reports (CERs), Medical Information Requests (MIRs), and quick research outputs.
“Life science teams are under pressure to deliver faster, higher-quality evidence for evolving global frameworks like the EU’s JCA,” said Gaugarin Oliver, Founder and CEO of MadeAi. “MadeAi’s latest release brings everything together—protocol design, screening, extraction, foundational literature reviews, and automated dossier generation—ensuring teams move seamlessly from literature review to reporting.”
MadeAi’s enhanced platform provides an end-to-end workflow that covers every step of the evidence synthesis lifecycle within a single secure system. Its unified workflow supports scoping, screening, extraction, validation, and reporting, while the new Life Science Agentic-AI Workflow promotes effective collaboration between AI and human experts.
To ensure accuracy and transparency, MadeAi uses large language model (LLM) orchestration and built-in quality controls, automatically selecting the best model for each specific task. The new release also introduces automated templates and structured outputs optimized for regulatory readiness across GVD, JCA, CER, and MIR submissions.
Built for enterprise use and validated by major global pharmaceutical and med-tech clients, MadeAi’s architecture emphasizes compliance, scalability, and security. The system employs multi-agent orchestration for adaptive reasoning, AI-aided and AI-as-Reviewer modes for faster screening, and integrated quality appraisal bias visualization for methodological rigor.
With these upgrades, MadeAi allows research and medical teams to move directly from literature review to submission-ready deliverables with improved traceability and consistency.
“MadeAi empowers HEOR, Market Access, and Medical Affairs teams to reduce manual workload, shorten timelines by up to 60 percent, and elevate evidence quality,” Oliver said. “Our mission is simple: to help life science organizations deliver evidence that’s faster, fairer, and fully defensible.”
